Vinci Pharmaceuticals wants to replace repeated eye injections with an implant. Can $8m bring EPIPLANT into the clinic?
Vinci Pharmaceuticals secures over $8 million to advance EPIPLANT retinal drug delivery toward human trials in 2027. See what comes next.